Loading...
XASXPGC
Market cap510mUSD
Dec 23, Last price  
0.50AUD
1D
0.00%
1Q
19.28%
Jan 2017
-38.14%
Name

Paragon Care Ltd

Chart & Performance

D1W1MN
XASX:PGC chart
P/E
97.77
P/S
0.28
EPS
0.01
Div Yield, %
1.54%
Shrs. gr., 5y
7.47%
Rev. gr., 5y
65.94%
Revenues
2.97b
+865.41%
249,584699,128371,060100,6231,126,2828,306,59314,661,39115,718,56617,096,44719,416,93132,223,35193,383,052117,192,924117,200,000236,009,000231,689,000235,840,000237,618,000307,630,0002,969,885,000
Net income
8m
-22.11%
-1,645,578-1,401,723-1,257,509-1,846,270-355,832147,782851,183-77,484739,6031,084,8912,103,1567,530,52310,174,76110,950,5558,862,000-77,269,0008,279,0006,634,00010,760,0008,381,000
CFO
44m
+150.45%
-2,058,209-1,281,847-1,000,453-591,329-432,699235,190145,752-310,749725,543-2,085,690809,8747,759,22111,989,3807,559,0001,158,0005,287,00027,463,00019,032,00017,749,00044,452,000
Dividend
Sep 18, 20230.006 AUD/sh
Earnings
Feb 27, 2025

Profile

Paragon Care Limited supplies durable medical equipment, medical devices, and consumable medical products to health and aged care markets in Australia, New Zealand, and internationally. The company offers clinical solutions for anaesthetists, intensivists, cardiac, vascular, and pain management; designs, manufactures, and distributes reagent red blood cells, monoclonal blood grouping reagents, and ancillary products for immunohaematology laboratories; and eye care products, such as ophthalmology and optometry, neonatal vision screening, and procedural kits. It also provides neonatal and paediatric assessment and treatment, including newborn hearing and vision screening, jaundice management, targeted temperature management, cerebral function monitoring, and seizure detection, as well as pain management and enteral feeding solutions; surgical products for hip and knee arthroplasty, infection prevention, pain management, biologics, and the operating room; and equipment repair and maintenance services. In addition, the company offers sterilisable transducers for surgical procedures such as neurology, hepatobiliary, renal, colorectal, vascular, laparoscopic, and robotic procedures; ultrasound systems, shockwave therapy, lasers, and accessories for infection control; and veterinary products, including point-of-care diagnostics, therapeutic lasers, oncology delivery products, centrifuges, autoclaves, IV lines and fluid therapy products, wearable CRI systems, and IT Solutions. Further, it provides telephony, nurse call, access control, CCTV, cordless, and Wi-Fi products. The company was formerly known as Citrofresh International Limited and changed its name to Paragon Care Limited in June 2008. Paragon Care Limited was incorporated in 1994 and is based in Melbourne, Australia.
IPO date
Oct 15, 1999
Employees
400
Domiciled in
AU
Incorporated in
AU

Valuation

Title
AUD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑062023‑062022‑062021‑062020‑062019‑062018‑062017‑062016‑062015‑06
Income
Revenues
2,969,885
865.41%
307,630
29.46%
237,618
0.75%
Cost of revenue
2,923,381
338,963
270,079
Unusual Expense (Income)
NOPBT
46,504
(31,333)
(32,461)
NOPBT Margin
1.57%
Operating Taxes
5,672
5,198
3,311
Tax Rate
12.20%
NOPAT
40,832
(36,531)
(35,772)
Net income
8,381
-22.11%
10,760
62.19%
6,634
-19.87%
Dividends
(12,613)
(7,886)
(1)
Dividend yield
3.07%
5.01%
0.00%
Proceeds from repurchase of equity
406
(483)
BB yield
-0.26%
0.26%
Debt
Debt current
116,754
21,719
26,209
Long-term debt
203,901
133,248
105,050
Deferred revenue
Other long-term liabilities
1,981
2,587
33,912
Net debt
297,081
130,197
84,795
Cash flow
Cash from operating activities
44,452
17,749
19,032
CAPEX
(6,779)
(21,046)
(4,611)
Cash from investing activities
(19,525)
(31,746)
7,070
Cash from financing activities
(5,953)
(10,002)
(11,930)
FCF
120,382
(194,577)
(68,371)
Balance
Cash
19,944
22,603
46,203
Long term investments
3,630
2,167
261
Excess cash
9,388
34,583
Stockholders' equity
291,918
262,059
249,653
Invested Capital
545,725
367,298
340,599
ROIC
8.94%
ROCE
8.52%
EV
Common stock shares outstanding
935,227
669,553
652,221
Price
0.44
87.23%
0.24
-16.07%
0.28
5.66%
Market cap
411,500
161.53%
157,345
-13.84%
182,622
5.66%
EV
708,581
296,650
273,721
EBITDA
60,972
(21,038)
(24,523)
EV/EBITDA
11.62
Interest
16,241
7,021
6,111
Interest/NOPBT
34.92%